Review

CD137\(^+\) T-Cells: Protagonists of the Immunotherapy Revolution

Alessio Ugolini\(^{1,2}\) and Marianna Nuti\(^{1,*}\)

\(^{1}\) Department of Experimental Medicine, “Sapienza” University of Rome, Viale Regina Elena, 324-00161 Rome, Italy; alessio.ugolini@moffitt.org
\(^{2}\) Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA
* Correspondence: marianna.nuti@uniroma1.it

Simple Summary: The CD137 receptor is expressed by activated antigen-specific T-cells. CD137\(^+\) T-cells were identified inside TILs and PBMCs of different tumor types and have proven to be the naturally occurring antitumor effector cells, capable of expressing a wide variability in terms of TCR specificity against both shared and neoantigenic tumor-derived peptides. The aim of this review is thus summarizing and highlighting their role as drivers of patients’ immune responses in anticancer therapies as well as their potential role in future and current strategies of immunotherapy.

Abstract: The CD137 receptor (4-1BB, TNF RSF9) is an activation induced molecule expressed by antigen-specific T-cells. The engagement with its ligand, CD137L, is capable of increasing T-cell survival, proliferation, and cytokine production. This allowed to identify the CD137\(^+\) T-cells as the real tumor-specific activated T-cell population. In fact, these cells express various TCRs that are specific for a wide range of tumor-derived peptides, both shared and neoantigenic ones. Moreover, their prevalence in sites close to the tumor and their unicity in killing cancer cells both in vitro and in vivo, raised particular interest in studying their potential role in different strategies of immunotherapy. They indeed showed to be a reliable marker able to predict patient’s outcome to immune-based therapies as well as monitor their response. In addition, the possibility of isolating and expanding this population, turned promising in order to generate effector antitumor T-cells in the context of adoptive T-cell therapies. CD137-targeting monoclonal antibodies have already shown their antitumor efficacy in cancer patients and a number of clinical trials are thus ongoing to test their possible introduction in different combination approaches of immunotherapy. Finally, the intracellular domain of the CD137 receptor was introduced in the anti-CD19 CAR-T cells that were approved by FDA for the treatment of pediatric B-cell leukemia and refractory B-cell lymphoma.

Keywords: CD137; 4-1BB; TILs; CD137\(^+\) T-cells; immunotherapy; ACT; CAR-T; monoclonal antibodies; biomarker

1. Introduction

Immunotherapy aims to re-educate the patient’s immune system to recognize and fight cancer cells. The existence of T-cells with a potential antitumor effect has laid the foundation for most of the current approaches of immunotherapy. In fact, the use of therapies such as immune checkpoint inhibitors (ICIs), DC vaccines, and adoptive T-cell transfer (ACT) finally relies on the presence of a population of effector T-cells that is capable of killing tumor cells. These immune-based drugs thus aim to unleash this population from different regulatory constraints such as T-cell exhaustion or the impossibility of reaching cancer cells, to subsequently limit tumor growth and progression. As a confirmation, the accumulation of tumor-infiltrating lymphocytes (TILs) correlates with a better clinical outcome and an improved survival in most tumor models [1–11], indicating their importance in predicting patients response to anticancer therapies. Nevertheless, the composition of TILs is heterogeneous [12] and it still remains challenging to identify the real population...
of naturally occurring antitumor T-cells [13]. Therefore, this review will discuss the emerging role of the CD137+ T-cells population as the main effector population activated against cancer cells with all the possible implications for the future of immunotherapy.

2. CD137: The Receptor

The CD137 receptor (4-1BB, TNFRSF9) is a member of the tumor necrosis factor receptors (TNFR) family and was characterized as an inducible costimulatory receptor on T-cells, together with its ligand (CD137L, 4-1BBL), both in human and mice [14]. CD137 was initially described as a surface marker expressed by activated T-cells, with an in vitro peak expression 48 h after the primary T-cell activation signal and a decline starting from day 4–5 [14–17]. In vivo, its expression upon activation turned out to happen even earlier, starting indeed at 12h post-immunization [18,19]. Both CD4+ and CD8+ T-cells are able to upregulate CD137, even if its expression on CD8+ T-cells is earlier and higher [20–22].

However, CD137 receptor is not a specific marker for T-cells, since it can be expressed, even if to a smaller extent, also by dendritic cells (DCs), monocytes, natural killer (NK) cells, eosinophils, and microglia [23]. On the other side, CD137L is expressed by activated antigen presenting cells (APC) as macrophages, DCs, and B-cells [20,23–26]. Therefore, it is reliable to suppose that the engagement between CD137 and its ligand is part of the complex pathways of interactions between APCs and T-cells.

Similarly to other members of the TNFR family, the CD137 receptor relies on TRAFs proteins to build its signaling [27]. The binding of both CD137L [28,29] and agonistic antibodies [30] results in a quick recruitment of TRAF1 and TRAF2 to the receptor. The consequent TRAF-mediated activation of NF-κB and MAPK intracellular signaling, leads to T-cell division and proliferation, an increased cell survival and enhanced effector functions in both CD4+ and CD8+ T-cells [15]. As for CD137 expression, also TRAF1 expression is induced by T-cell activation, confirming that the CD137-induced signalosome is required for cytotoxic T-cells (CTL) expansion and for the boosting of effector functions [27]. In fact, a number of mice experiments proved that CD137 stimulation is able to increase T-cell proliferation and cytokine production [14,23]. Consistently, in absence of the CD28 signal, T-cells treated with an anti-CD3 and CD137L can proliferate and produce interleukin 2 (IL-2) to a similar extent of those treated with the combination of anti-CD3 and anti-CD28, but just in the presence of a consistent antigen stimulation [31–34]. This evidence was one of the starting points to get to the notion that CD137 identifies those T-cells that are activated against a specific antigen. The CD137L stimulation of human CD8+ T-cells leads to the expansion of this T-cells subset which is followed by an increase of effector molecules such as granzyme A, interferon γ (IFN-γ), perforin, and different cytokines, driving CD8+ memory T-cells toward a differentiated effector phenotype [35,36]. In addition, the CD137 receptor seems to have a strong and prevalent role in increasing T-cell survival by preventing activation-induced T-cell death [37,38] and this appears to be in line with the physiological timing of the CD137 signal that is subsequent to the TCR and CD28 mediated signals. The BIM downregulation and the induction of Bcl-XL and Bfl-1 were pointed out as responsible for the inhibition of the activation-induced cell death, after the CD137 engagement [39]. Further studies also showed that the CD137 engagement is able to stimulate the mitochondrial metabolism in order to increase T-cell respiratory capacities [40,41] and to induce DNA demethylation in CD8+ T-cells main genes and chromatin reprogramming [42]. As above mentioned, different studies highlighted a preferential role of CD137 in CD8+ T cells rather than in CD4+ T cells, even if it can be induced on both the T-cell subsets, including CD4+ regulatory T-cells (Tregs) [43]. However, the effective function of CD137 signaling on CD4+ T-cells is still unclear and may thus not be as physiologically relevant as for CD8+ T cells [44].

As confirmation, mice deficient for CD137 show an impaired antiviral response mediated by CD8+ T cells [45–47]. Similarly, mice deficient for CD137L that were adoptively transferred with OT-1 derived CD8+ T-cells, showed a marked reduction of these OVA-specific T-cells in both the late primary response and the secondary expansion to OVA/LPS [19]. Moreover, when anti-CD137 monoclonal antibodies or CD137L injec-
tions were tested in cancer therapy, a significant benefit in terms of antitumor response was noticed [21,24,38,48–57]. When CD137 was targeted by in vivo treatments with an agonistic anti-CD137 monoclonal antibody, it resulted in an increased effect on CD8+ T-cells expansion and activation with just a modest effect on CD4+ T-cells, thus confirming that in vivo its signal affects predominantly this subset of T-cells [50,58].

Finally, as evidence about the importance of the CD137 receptor in marking those T-cells that were activated to eliminate a non-self-antigen, it was reported that the CD137 resulted specifically upregulated after an alloantigen stimulation and, upon CD137 depletion, it was possible to remove alloreactive T-cells during hematopoietic transplantation [59].

An important step forward in the field of tumor immunology, was made when CD137+ T-cells were clearly identified as those cells that were terminally differentiated and antigen-specific effector cells, regardless of the antigen specificity [60]. This allowed the isolation of those cells that were considered the real effector cells activated against tumor antigens [61].

3. CD137+ T-Cells: The Natural Tumor-Specific Population

The discovery that CD137 is expressed by most of activated and antigen-specific (both against viral and tumor antigens) CD8+ T-cells, allowed the isolation of tumor-specific effector T-cells from blood, without knowing the immunogenic epitopes or the MHC-restriction complex. These cells, even if present at low frequencies, were able to kill antigen-expressing cancer cells upon expansion, although this required an ex vivo restimulation with the defined tumor antigen [60,61].

This evidence raised a strong interest in investigating this cell repertoire also inside the tumor. In fact, the tumor microenvironment (TME) is enriched for T-cells specific for defined antigens with cytolytic ability against cancer cells [62]. In addition, even if defined antigens are known for different tumor models, exomic sequencing data in different solid tumors proved that cancer cells express a various and heterogeneous set of mutated neo-antigens that are characteristic for every single patient and thus can be recognized by TILs that are able to exert an antitumor response [63]. As confirmation, T-cell receptors (TCRs) isolated from CD137+ TILs, showed a reactivity against various mutations of tumor-derived antigens [64]. Given this evidence, the possibility of identifying a tumor-specific T effector population inside the TME without the knowledge of the antigen epitopes seemed very promising.

Initial evidence proved that CD137 is strongly expressed by TILs if compared to spleen- or lymph nodes-derived T-cells and its expression is induced by hypoxia through hypoxia-inducible factor 1α [65].

Recently, Ye et al. decided to investigate the CD137+ T-cells population in ovarian cancer patients, comparing three different locations in which this subset of cells could be found: TME, ascites, and peripheral blood [66]. They demonstrated that CD137+ T-cells are present in small percentages in the peripheral blood and, to a larger extent, in ascites and even more inside the tumor, showing a progressive hierarchy with the T-cells in a closer proximity to cancer cells expressing the higher percentages of CD137 and then decreasing gradually toward the periphery. Overnight incubation with autologous cancer cells largely increased the percentage of CD137+ T-cells and their ability of producing a consistent amount of IFN-γ. Additionally, CD137 expression was further increased when T-cell lines with a known antigen specificity were used. Most importantly, when human TILs and tumor cells where transferred into immunodeficient mice, only CD137+ T-cells (but not CD137− T-cells) were able to inhibit tumor growth [66]. Thus, they demonstrated that CD137+ T-cells are those cells that naturally show the real antitumor reactivity, confirming also that they represent a subset of newly recruited antitumor T-effector cells, being CD137 expression a rapid and transient event upon specific activation. Overall, this study proposed a novel method to isolate and expand tumor reactive TILs that can be used for adoptive T-cell transfer approaches; the vast heterogeneity of TCRs is indeed conserved with this strategy thus helping to prevent the escape of those tumor cells that do not express a determined antigen or those that express mutated antigens.
These findings suggested the potential role of CD137+ T-cells as key contributors of the antitumor immune responses and thus as potential determiners of the success of immunotherapies as well as novel protagonists of immune-based approaches (Figure 1).

Despite these clear results showing the importance of the CD137+ T-cell population in eliciting an antitumor response, evidence about the role of these T-cells in oncologic patients have only recently emerged (Table 1).

In 2020, for the first time we provided evidence about the importance of CD137+ T-cells in determining the outcome of metastatic non-small cells lung cancer (NSCLC) patients undergoing immunotherapies [67,68]. Patients that were positive for the autoantibody IgM-Rheumatoid Factor (IgM-RF) showed indeed a reduced frequency of CD137+ T-cells in peripheral blood and an increased tendency to develop an early progression, in addition to a markedly reduced progression-free survival (PFS) and overall survival (OS) after the anti-PD-1 treatment [68]. In addition, to confirm the importance of this population as an independent prognostic factor, it was reported how a higher percentage of CD137+ T-cells in peripheral blood mononuclear cells (PBMC) at baseline, was alone associated with a prolonged OS as well as PFS of patients in treatment with an anti-PD-1 ICI [68].

In addition, in 2018 it was proven that, in metastatic renal clear cell carcinoma (mR-CCC) patients undergoing the anti-PD-1 treatment, the percentage of CD137+ T-cells decreased during tumor progression [69]. Moreover, patients pretreated with Tyrosin-kinase inhibitor Pazopanib, showed a robust increase in DC activation profile and a subsequent in-

Figure 1. Schematic representation of CD137+ T-cell activation as a result of priming by TAA-carrying activated APC. The consequence of the CD137/CD137-L engagement is a marked increase in cell survival, followed by an increased proliferation, cytokine production, and effector molecules release. Then, possible roles of CD137+ T-cells population in the present and future of immunotherapy. APC, antigen presenting cell; TAA, tumor-associated antigens; MHC, major histocompatibility complex; ACT, adoptive cell therapy; moAb, monoclonal antibodies; ICI, immune checkpoint inhibitors; CAR, chimeric antigen receptor.4. CD137+ T-cells can predict cancer patients’ response to immune-based therapies.
crease of the frequency of CD137+ T-cells when compared to Sunitinib [69]. Still in mRCCC, Zizzari et al. demonstrated that CD137+ T-cells were positively associated with patients response to TKI [70]. In fact, responder patients showed a markedly higher percentage of this T-cell subset when compared to non-responders. These results highlight the importance of this T-cell subset in oncologic patients response to therapies that require, even if in an indirect way, the immune system’s ability of killing tumor cells. In this scenario, the percentage of this population in peripheral blood (and most likely also in other districts as draining lymph nodes and TME) could serve as a possible biomarker able to identify those patients that would benefit the most from a determinate treatment that relies on T-cells as final effectors.

Table 1. Summary of the results showing the power of CD137+ T-cells population as a biomarker able to predict and monitor patients’ response to different immune-based therapies in various tumor models.

| Cancer Type         | Treatment                  | Results                                                                 | References                        |
|---------------------|----------------------------|-------------------------------------------------------------------------|-----------------------------------|
| Metastatic NSCLC    | Anti-PD-1 ICIs             | Higher percentages of CD137+ T-cells in PBMC predicted a prolonged patients’ OS and PFS. | [67,68] Ugolini et al., 2020       |
| Metastatic RCCC     | Anti-VEGF-R TKIs and anti-PD-1 ICIS | Percentage of CD137+ T-cells in PBMC decreased during patients’ progression. | [69] Zizzari et al., 2018         |
| Metastatic RCCC     | TKIs                       | Higher percentages of CD137+ T-cells in PBMC were associated with responder patients. | [70] Zizzari et al., 2020         |
| Metastatic Melanoma | Anti-PD-1 ICIS             | CD137 mRNA levels at the tumor site were positively associated with a prolonged OS, PFS, and a better response to the therapy. | [71] Fröhlich et al., 2020        |

Finally, in 2020, indirect evidence of the CD137+ T-cells power in determining a prolonged survival for cancer patients came from a study on melanoma patients where it was shown that TNFRSF9 low methylation levels and the subsequent increased mRNA expression at the tumor site, that was prevalently identified inside T-cells, correlated with a better OS of patients as well as a better PFS and response to the anti-PD-1 treatment [71]. TNFRSF9 mRNA expression positively correlated also with the frequency of effector and memory tumor infiltrating lymphocytes, while it was inversely correlated with the frequency of naive tumor infiltrating lymphocytes [71]. As a confirmation of its power as biomarker for the identification of activated effector T-cells, TNFRSF9 mRNA expression levels positively correlated with an increased IFN-γ signature [71].

These results indicate the potential role of this population as the driver of a successful immunotherapy, thus suggesting the possibility of investigating its presence in patients before undergoing immune-based treatments. In fact, a reduction in its frequency could account for the impossibility of getting a complete or even partial response at least in part of the oncologic patients. In this scenario, strategies aimed at increasing their numbers could be considered at an initial stage, in order to make the patient more prone to efficiently receive an immunotherapeutic treatment.

4. CD137+ T-Cell-Based Therapies as Possible Protagonists for Future Immunotherapies

As previously mentioned, TILs represent the ideal candidates for adoptive cell transfer immunotherapies since they are enriched for T-cells specific for tumor-derived antigens, showing a vast antigen specificity. Moreover, upon ex vivo restimulation, they show potent antitumor activity and they can be largely expanded in order to get a consistent amount of cells to be administered to the patient [72,73]. Specifically, they raise a particular interest in those tumors that are poorly immunogenic and thus cannot benefit from the usage
of immune checkpoint inhibitors as single agents [74]. In fact, it was initially tested in refractory metastatic melanoma patients, in which the use of TILs that were extracted and then rapidly expanded with feeder cells and high doses of IL-2 [75], revealed capable of generating enough cells for reinfusion. It thus resulted also effective in terms of disease control in particular when accompanied by non-myeloablative lymphodepletion and then followed by a treatment with high-dose IL-2 [76]. The efficacy of TILs-based adoptive cell therapy (ACT) was confirmed by different independent trials showing response rates of 40–50% in metastatic melanoma patients, reaching even a complete tumor regression in 10–25% of patients [76–81]. It is important to highlight that the results of all these independent studies demonstrate that a consistent part of the responses observed are durable, in particular in those patients showing a complete tumor regression that remained free from disease for many years after the treatment [82–85].

Additionally, in ovarian cancer, it is possible to isolate and expand a sufficient number of TILs for ACT, with encouraging clinical results in terms of patients outcome [86–91]. In addition, a large-scale expansion of TILs was reported for other different solid cancer types, including breast, cervical, colon renal and sarcoma, even if the results in terms of clinical outcome for TIL-based ACT in these subsets of patients were modest [92–95]. These findings prove the potential clinical efficacy of ACT that involves TILs for these and other cancer types, even if the identification and expansion of specific antitumor TILs is the actual challenge for the next future of this treatment. ACT involving the entire repertoire of TILs is indeed limited by the time and the difficulties in isolating and expanding tumor-reactive functional cells [96]. Certainly, a prerequisite for ACT to be effective is isolating and thus obtaining, upon expansion, an adequate number of tumor-specific effector T-cells from the patient. The problem of isolating the entire population of TILs is that this population is composed by a heterogeneous group of different subpopulations. Memory T-cells, anergic T-cells, exhausted T-cells, and even a consistent amount of immunosuppressive Foxp3 + and Foxp3 − T-cells are present in the reservoir of total TILs in different cancer types, thus limiting the frequency of antitumor effector cells [97,98]. Furthermore, a long term ex vivo stimulation in order to expand the tumor-reactive subpopulation of TILs and thus getting a sufficient number of effector cells, drives cells toward exhaustion and a loss of the wide range of antigen-specific TCRs [81,97]. Notably, cases of recurrences in cancer patients due to antigen loss and neoantigen mutations were widely documented, supporting the limitation of using T-cell clones with a limited epitope recognition, as in the case of CAR-T cells. Moreover, tumor-associated antigens for different solid cancers are still not fully characterized [81,97].

Thus, the rational for an effective TILs-based ACT would be identifying and isolating the ideal T-cell subset capable of maximizing the tumor cells killing, while eliminating anergic and suppressive T-cells from the TILs repertoire. Therefore, it would be beneficial to look at possible biomarkers in order to identify tumor-specific T-cells without the necessity of identifying tumor-derived antigens epitopes.

Of note, many efforts were made in order to recognize tumor-reactive T-cells. The identification of rare T-cells carrying neoantigen-specific TCRs relies on the detection of specific somatic mutations of cancer cells. The problem is that these mutations show a wide variability among different patients even when considering tumors with similar features. The process would indeed require advanced and expensive technologies that are not only labor intensive, but also time consuming. Thus, it would require additional weeks besides those covered by the routine TILs separation and expansion. Consequently, more efficient methods in terms of labor and time consumption for the identification and isolation of antitumor TILs are required to give this ACT approach a clinical feasibility and validity.

Following antigen-induced activation and stimulation, human effector T-cells undergo phenotypic and functional changes, including the upregulation of surface markers. As previously discussed, the overexpression of CD137 receptor on antigen-specific activated T-cells provides the opportunity to clearly identify and isolate tumor-reactive effector cells by magnetic separation or fluorescence-activated cell sorting (FACS), thus removing the
need of an ex vivo restimulation with defined antigen in order to reveal this subset of T-cells. A short term coculture with tumor cells in this case would be needed just in order to further stimulate the upregulation of CD137, since it was previously described that this receptor is strongly upregulated upon T-cells culturing together with tumor cells that express shared and neoantigenic peptides [64,66]. In addition, CD137+ isolation would not require samples rich of TILs, which may be difficult to obtain from surgical resections, in order to be sure to get the adequate number of effector cells. In fact, their isolation, that is possible not only at the tumor site but also from lymph nodes and even from peripheral blood, would be a precise isolation of tumor-reactive cells that need just to be expanded.

Based on these observations, Seliktar-Ofir et al. have reported for the first time a simple, robust, and fast method that allows the tumor-reactive enrichment for a therapeutic purpose [99]. They demonstrated that only 30.1 ± 25.9% of the TILs expressed CD137 after cocultures, but almost all cells expressed the receptor after the selection. In addition, they showed that CD137+ selected T-cells had an increased antitumor reactivity and contained a higher frequency of both shared and neoantigen reactive T-cells [99]. In this way, the CD137+ selection enables the isolation of antitumor effector T-cells without the need of knowing the epitopes of tumor-derived antigenic peptides.

These promising findings open novel prospective for the optimization of ACT in the near future.

5. CD137 in Current Clinical Practice: CD137-Targeting Antibodies and CD137 CAR-T Cells

In conclusion, it is important to mention the CD137-based approaches that are currently available for the clinical practice. Nowadays we have two different strategies involving the CD137 receptor [44]. First, the CD137 domain was included in the chimeric antigen receptors (CAR) T-cells. Second, monoclonal antibodies (MoAb) as well as bispecific antibodies targeting the CD137 receptor were proposed in the clinic as a strategy of cancer immunotherapy in different cancer types.

The only approach involving the CD137 receptor that has so far been approved by the FDA is the CAR-T cells therapy targeting the CD19 for the treatment of pediatric B-cell leukemia and refractory B-cell lymphoma [100]. In this approach, the introduction of the CD137 intracellular domain, that is able to keep the survival signaling in these engineered T-cells, led to an increased persistence of therapeutical CAR-T cells when compared to those including the CD28 domain [101]. Additionally, CAR-T cells containing the CD137 signaling domain showed an advantage for both a metabolic point of view and also an advantageous epigenetic switch that increased a memory development by CAR-T cells [102].

Regarding the use of anti-CD137 MoAb in a clinical setting has raised particular interest, since it appeared capable of having a beneficial effect on tumor regression and oncological patient response, both when used as single agent and even more when combined to other drugs or anticancer treatments [44,54,55,65,103–132]. This clinically relevant effect is due to the ability of the antibody of stimulating an anticancer response that relies on effector T-cells [44,111]. After the stimulation with this MoAb, are not only the antitumor effector T-cells to be expanded, but importantly increased is also the frequency and the activity of tumor-specific memory T-cells that are able to confer a prolonged protection against cancer cells and thus a prolonged antitumor response [54].

Interestingly, the use of the anti-CD137 MoAb turned capable of reducing the activation and proliferation of both regulatory T-cells and myeloid-derived suppressor cells [55,103,110,133,134], that recently emerged as not only able to impair T-cell function but also of compromising the ICI efficacy through the impairment of DC function in cancer [135]. In addition, it was shown that the treatment with an anti-CD137 is able to increase the recruitment of effector T-cells inside the TME by targeting the receptor expressed by tumor-associated endothelial cells [104].
The mechanisms that can suppress antitumor immune responses in the context of cancer are various and this gives the rationale to the use of CD137 targeting in combination with other strategies aimed at removing these regulatory constraints \[44,109,111–113,117,136,137\].

So far, two different CD137-targeting agonistic MoAb have been introduced in the clinic: utolimumab (PF-05082566), a humanized IgG1 MoAb and urelumab (BMS-663513), a fully human IgG4 MoAb \[44\]. Being agonistic antibodies, both utolimumab and urelumab activate the CD137 signaling, promoting T-cell survival, proliferation, and cytokine production; while utolimumab blocks the CD137-CD137L interaction, urelumab, that appears to be a weaker agonist, does not prevent this engagement \[44\]. Phase I and II trials that tested the efficacy of urelumab in oncologic patients with advanced cancer demonstrated a notable effect of the MoAb as single agent, even if the trials were suspended due to the adverse liver inflammation that was noticed in treated patients \[56\]. The same adverse effects on liver inflammation induced by urelumab at doses of \(\geq 1\) mg/kg were spotted in a safety analysis that showed how a safe usage of the drug needed a marked decrease of the dose to \(0.1\) mg/kg \[138\]. Unfortunately, this dose decrease reduced the efficacy of urelumab as single agent, but permitted its use in combination with the anti-PD-1 targeting that gave promising clinical results in patients with advanced melanoma \[57\]. The ongoing trial that are testing Urelumab in combination with other agents are reported by Etxeberria et al. in Table 1 of their review \[44\].

Differently from urelumab, utolimumab showed no dose-related toxicity \[44\]. As single agent, it showed just little benefit in terms of clinical outcome for advanced cancer patients in phase I trials and this should probably be referred to its weakness as CD137 agonist \[44,139,140\]. On the contrary, Phase I trials testing utolimumab in combination with pembrolizumab \[141,142\] or with mogamulizumab in advanced solid tumor patients \[143\] and with rituximab in patients affected by relapsed or refractory non-Hodgkin’s lymphoma \[144\] showed no toxicity and thus safety and tolerability. In addition, promising antitumor effects and clinical responses were shown in all these studies. Other combination strategies that are currently ongoing in different trials are reported by Etxeberria et al. in Table 1 of their review \[44\].

Regarding bispecific antibodies, various approaches were recently hypothesized and are now under evaluation. In particular, the first and most advanced on those introduced the possibility of targeting the CD137 receptor on one side, and a tumor antigen (HER2) on the other side, in order to target this activation receptor specifically in the context of the TME \[145\]. This treatment has already shown clinical benefits in a Phase I trial in patients with HER2\(^+\) malignancies \[146\]. In line with that, other bispecific antibodies targeting the CD137 receptor together with other tumor antigens or the cancer associated fibroblast marker FAP (fibroblast activation protein), were tested in preclinical settings, showing promising results \[147–149\]. Since activated CD137\(^+\) T-cells can still be ineffective due to the exhaustion induced by the tumor, bispecific antibodies targeting the CD137 receptor together with PD-L1 are actually under evaluation (NCT03809624).

The weakness of using CD137-targeting in vivo should refer to the fact that the effectiveness of this targeting largely relies on the baseline presence of a sufficient number of naturally occurring antitumor CD137\(^+\) T-cells that are available to be unleashed and that are not suppressed by other mechanisms. Unfortunately, as previously reported, this scenario does not often reflect what really happens in cancer patients and thus requires combination of this approach with other strategies.

6. Conclusions

With these emerging findings it is becoming clear that CD137\(^+\) T-cells play a pivotal role in exerting a specific antitumor activity as the final effectors of the complex immune response. Since most of the drugs that are available today for the treatment of oncological patients have the immune system as their target or, at least, rely on the patient’s immune system fitness in order to eliminate cancer cells, this population starts raising particular interest as a possible predictor of the responses to anticancer treatments. Moreover, their
ability to predict the outcome and to monitor the responses to immune-based drugs, could be useful to aid clinicians in better stratifying patients and consequently selecting the best therapeutic approach. However, more efforts will be required in the future to validate their role as a possible biomarker in various cancer types.

In addition, it will also be critical for the success of immunotherapies to optimize novel strategies of immunotherapy that have CD137 T-cells as their protagonist. In fact, even if protocols for their isolation, expansion, and targeting have already been standardized and proven to be effective, other trials involving CD137 T-cells based ACT and anti-CD137 agonistic mAb, will be required in the near future to probe their potential in different clinical settings.

In conclusion, in light of the evidence reported in this review, it is important to state that trying to directly expand in vivo the antitumor effector T-cell population thanks to single agent strategies is not efficient in terms of patients’ clinical outcome. This is probably due to the fact that these cells need to reach the tumor area and then proliferate and exert their effector functions in order to observe a clinical response. An altered vascularization, T-cell exhaustion, and an immune suppressive tumor microenvironment, that are able to impair immune responses, are just some of the reasons why single agent strategies have recently proven to be ineffective [135,150–154]. In this scenario, the possibility of uncovering a receptor that characterizes the real antitumor T-cells population, will allow to target more precisely these cells with a combination of different strategies aimed to facilitate cancer cells’ elimination and preventing immune suppression.

Of note, it is important to highlight that other second line costimulatory receptors, as in the case of OX40 (CD134, TNFRSF4), showed to be regulated in a similar way if compared to CD137 receptor, having thus a similar therapeutic potential [155–158] and questioning the uniqueness of the CD137 receptor in pointing out the natural occurring antitumor T-cells. However, the aim of this review was to present the latest findings on how the CD137 receptor is alone able to identify a population capable of recognizing and eliminating cancer cells, thus discussing the potential use of this population as a biomarker to evaluate the patients’ capability to respond to immune-based therapies as well as the potential benefit of introducing CD137 T-cells as protagonists of novel strategies for the treatment of oncologic patients.

Author Contributions: Conceptualization, visualization, review and editing: A.U. and M.N.; original draft preparation: A.U. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by MIUR—“Sapienza” (M.N., C26H15Y42B).

Acknowledgments: The authors want to thank Renzo Paliza Vasquez for the language correction.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Schalper, K.A.; Brown, J.; Carvajal-Hausdorf, D.; McLaughlin, J.; Velcheti, V.; Syrigos, K.N.; Herbst, R.S.; Rimm, D.L. Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer. J. Natl. Cancer Inst. 2015, 107. [CrossRef] [PubMed]
2. Boxberg, M.; Leising, L.; Steiger, K.; Jesinghaus, M.; Alkhamas, A.; Mielke, M.; Pfarr, N.; Götz, C.; Wolff, K.D.; Weichert, W.; et al. Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma. J. Immunol. 2019, 202, 278–291. [CrossRef] [PubMed]
3. Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M.N.; et al. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. N. Engl. J. Med. 2003, 348, 203–213. [CrossRef] [PubMed]
4. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pagès, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science 2006, 313, 1960–1964. [CrossRef] [PubMed]
5. Pagès, F.; Galon, J.; Dieu-Nosjean, M.-C.; Tartour, E.; Sautès-Fridman, C.; Fridman, W.-H. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene 2009, 29, 1093–1102. [CrossRef]
32. Halstead, E.S.; Mueller, Y.; Altman, J.D.; Katsikis, P.D. In Vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. *Nat. Immunol.* 2002, 3, 536–541. [CrossRef]

33. Bertram, E.M.; Lau, P.; Watts, T.H. Temporal Segregation of 4-1BB Versus CD28-Mediated Costimulation: 4-1BB Ligand Influences T Cell Numbers Late in the Primary Response and Regulates the Size of the T Cell Memory Response Following Influenza Infection. *J. Immunol.* 2002, 168, 3777–3785. [CrossRef]

34. Maus, M.V.; Thomas, A.K.; Leonard, D.G.; Allman, D.; Addya, K.; Schlienger, K.; Riley, J.L.; June, C.H. Ex Vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. *Nat. Biotechnol.* 2002, 20, 143–148. [CrossRef]

35. Bukczynski, J.; Wen, T.; Watts, T.H. Costimulation of human CD28 T cells by 4-1BB ligand. *Eur. J. Immunol.* 2003, 33, 446–454. [CrossRef]

36. Bukczynski, J.; Wen, T.; Ellefsen, K.; Gauldie, J.; Watts, T.H. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. *Proc. Natl. Acad. Sci. USA* 2004, 101, 1291–1296. [CrossRef]

37. Hurtado, J.C.; Kim, Y.J.; Kwon, B.S. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. *J. Immunol.* 1997, 158, 2600–2609.

38. May, K.F.; Chen, L.; Zheng, P.; Liu, Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. *Cancer Res.* 2002, 62, 3459–3465.

39. Lee, H.-W.; Park, S.-J.; Choi, B.K.; Kim, H.H.; Nam, K.-O.; Kwon, B.S. 4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bcl-2. *J. Immunol.* 2002, 169, 4882–4888. [CrossRef] [PubMed]

40. Menk, A.V.; Scharping, N.E.; Rivadeneira, D.B.; Calderon, M.J.; Watson, M.J.; Dunstane, D.; Watkins, S.C.; Delgoffe, G.M. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. *J. Exp. Med.* 2018, 215, 1091–1100. [CrossRef] [PubMed]

41. Teijeira, A.; Labiano, S.; Garasa, S.; Etxebiria, I.; Santamaría, E.; Rouzaut, A.; Enamorado, M.; Azpilikueta, A.; Inogés, S.; Bolaños, E.; et al. Mitochondrial Morphological and Functional Reprogramming Following Costimulating CD137 (4-1BB) Costimulation. *Cancer Immunol. Res.* 2018, 6, 798–811. [CrossRef] [PubMed]

42. Aznar, M.A.; Labiano, S.; Diaz-Lagares, A.; Molina, C.; Garasa, S.; Azpilikueta, A.; Etxebiria, I.; Sánchez-Paulete, A.R.; Korman, A.J.; Esteller, M.; et al. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes. *Cancer Immunol. Res.* 2018, 6, 69–78. [CrossRef] [PubMed]

43. Freeman, Z.T.; Nirschl, T.R.; Hovelson, D.H.; Johnston, R.J.; Engelhardt, J.J.; Selby, M.J.; Kochel, C.M.; Lan, R.Y.; Zhai, J.; Ghasemzadeh, A.; et al. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. *Clin. Cancer Res.* 2020, 130, 1405–1416. [CrossRef] [PubMed]

44. Etxebiria, I.; Glez-Vaz, J.; Teijeira, A.; Melero, I. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. *ESMO Open* 2019, 4 (Suppl. 3), e000733. [CrossRef] [PubMed]

45. Debenedette, M.A.; Wen, T.; Bachmann, M.F.; Ohashi, P.S.; Barber, B.H.; Stocking, K.L.; Peschon, J.J.; Watts, T.H. Cell Response to Influenza Virus. *J. Immunol.* 1999, 163, 4833–4841.

46. Tan, J.T.; Whitmire, J.K.; Ahmed, R.; Pearson, T.C.; Larsen, C.P. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8+ T cell responses. *J. Immunol.* 1999, 163, 4859–4868.

47. Kwon, B.S.; Hurtado, J.C.; Lee, Z.H.; Kwack, K.B.; Seo, S.K.; Choi, B.K.; Koller, B.H.; Wolisi, G.; Broxmeyer, H.E.; Vinay, D.S. Immune Responses in 4-1BB (CD137)-Deficient Mice. *J. Immunol.* 2002, 168, 5483–5490. [CrossRef] [PubMed]

48. Melero, I.; Bach, N.; Hellström, K.E.; Aruffo, A.; Mittler, R.S.; Chen, L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway. *Eur. J. Immunol.* 1999, 28, 1116–1121. [CrossRef] [PubMed]

49. Wiethe, C.; Dittmar, K.; Doan, T.; Lindenmaier, W.; Tindle, R. Enhanced Effector and Memory CTL Responses Generated by Incorporation of Receptor Activator of NF-κB (RANK)/RANK Ligand Costimulatory Molecules into Dendritic Cell Immunogens Expressing a Human Tumor-Specific Antigen. *J. Immunol.* 2003, 171, 1421–1430. [CrossRef] [PubMed]

50. Melero, I.; Shuford, W.W.; Newby, S.A.; Aruffo, A.; Ledbetter, J.A.; Hellström, K.E.; Mittler, R.S.; Chen, L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. *Nat. Med.* 1997, 3, 682–685. [CrossRef] [PubMed]

51. Yonezawa, A.; Dutt, S.; Chester, C.; Kim, J.; Kohrt, H.E. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. *Clin. Cancer Res.* 2015, 21, 3131–3140. [CrossRef] [PubMed]

52. Sanchez-Paulete, A.R.; Labiano, S.; Rodriguez-Ruiz, M.E.; Azpilikueta, A.; Etxebiria, I.; Bolaños, E.; Lang, V.; Rodriguez, M.; Aznar, M.A.; Jure-Kunkel, M.; et al. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. *Eur. J. Immunol.* 2016, 46, 513–522. [CrossRef] [PubMed]

53. Li, S.-Y.; Liu, Y. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. *Clin. Pharmacol. Adv. Appl.* 2013, 5 (Suppl. 1), 47–53. [CrossRef] [PubMed]

54. Narazaki, H.; Zhu, Y.; Luo, L.; Zhu, G.; Chen, L. CD137 agonist antibody prevents cancer recurrence: Contribution of CD137 on both hematopoietic and nonhematopoietic cells. *Blood* 2010, 115, 1941–1948. [CrossRef] [PubMed]

55. Gaujard, V.; Judor, J.-P.; Le Guen, V.; Cany, J.; Ferry, N.; Conchon, S. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. *Int. J. Cancer.* 2014, 135, 2857–2867. [CrossRef] [PubMed]

56. Szol, M.; Hodi, F.S.; Margolin, K.; McDermott, D.F.; Ernstoff, M.S.; Kirkwood, J.M.; Woljaszek, C.; Feltquate, D.; Logan, T. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). *J. Clin. Oncol.* 2008, 26, 3007. [CrossRef] [PubMed]
57. Massarelli, E. Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies. In Proceedings of the 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, National Harbor, MD, USA, 9–13 November 2016.

58. Shustof, W.W.; Klussman, K.; Titchler, D.D.; Loo, D.T.; Chalupny, J.; Siadak, A.W.; Brown, T.J.; Emswiler, J.; Raecho, H.; Larsen, C.P.; et al. 4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses. J. Exp. Med. 1997, 186, 47–55. [CrossRef]

59. Wehler, T.C.; Nonn, M.; Brandt, B.; Britten, C.M.; Görente, M.; Todorova, M.; Link, I.; Khan, S.A.; Meyer, R.G.; Huber, C.; et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 2007, 109, 365–373. [CrossRef]

60. Wolff, M.; Kuball, J.; Ho, W.Y.; Nguyen, H.; Manley, T.J.; Bleakley, M.; Greenberg, P.D. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007, 110, 201–210. [CrossRef]

61. Watanabe, K.; Suzuki, S.; Kamei, M.; Toji, S.; Kawase, T.; Takahashi, T.; Kuzushima, K.; Akatsuka, Y. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. Int. J. Hematol. 2008, 88, 311–320. [CrossRef]

62. Romero, P.; Dunbar, P.R.; Valmori, D.; Pittet, M.; Ogg, G.S.; Rimoldi, D.; Chen, J.-L.; Liénard, D.; Cerottini, J.-C.; Cerundolo, V. Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes. J. Exp. Med. 1998, 188, 1641–1650. [CrossRef] [PubMed]

63. Robbins, P.F.; Lu, Y.C.; El-Gamil, M.; Li, Y.F.; Gross, C.; Gartner, J.; Lin, J.C.; Teer, J.K.; Cliften, P.; Tycksen, E.; et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 2013, 19, 747–752. [CrossRef] [PubMed]

64. Parkhurst, M.R.; Gros, A.; Pasetto, A.; Prickett, T.; Crystal, J.S.; Robbins, P.; Rosenberg, S.A. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. Clin. Cancer Res. 2017, 23, 2491–2505. [CrossRef] [PubMed]

65. Palazón, A.; Martínez-Forero, I.; Teijeira, A.; Morales-Kastresana, A.; Alfaro, C.; Sanammad, M.F.; Perez-Gracia, J.L.; Peñuelas, I.; Hervás-Stuibs, S.; Rouzaut, A.; et al. The HIF-1a Hypoxia Response in Tumor-Infiltrating Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy. Cancer Discov. 2012, 2, 608–623. [CrossRef] [PubMed]

66. Ye, Q.; Song, D.-G.; Poussin, M.; Yamamoto, T.; Best, A.; Li, C.; Coukos, G.; Powell, D.J. CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumors. Clin. Cancer Res. 2014, 20, 44–55. [CrossRef]

67. Ugolini, A.; Zizzari, I.; Ceccarelli, F.; Botticelli, A.; Colasanti, T.; Strigari, L.; Rughetti, A.; Rahimi, H.; Conti, F.; Valesini, G.; et al. 4P IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+ T-cells. Ann. Oncol. 2020, 31, S1418. [CrossRef] [PubMed]

68. Ugolini, A.; Zizzari, I.G.; Ceccarelli, F.; Botticelli, A.; Colasanti, T.; Strigari, L.; Rughetti, A.; Rahimi, H.; Conti, F.; Valesini, G.; et al. IgM-rheumatoid factor confers primary resistance to anti-PD1 immunotherapies in NSCLC patients by reducing CD137+ T-cells. EBioMedicine 2020, 62, 103098. [CrossRef]

69. Zizzari, I.G.; Napoletano, C.; Botticelli, A.; Caponnetto, S.; Calabrò, F.; Gelibter, A.; Rughetti, A.; Ruscito, I.; Rahimi, H.; Rossi, E.; et al. TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway. Cancer Immunol. Res. 2018, 6, 711–722. [CrossRef]

70. Zizzari, I.G.; Napoletano, C.; Di Filippo, A.; Botticelli, A.; Gelibter, A.; Calabrò, F.; Rossi, E.; Schinzari, G.; Urbano, F.; Pomati, G.; et al. Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma. Cancers 2020, 12, 2620. [CrossRef]

71. Fröhlich, A.; Loick, S.; Bawden, E.G.; Fietz, S.; Dietrich, J.; Diekmann, E.; Saavedra, G.; Fröhlich, H.; Niebel, D.; Sirokay, J.; et al. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine 2020, 52, 102647. [CrossRef]

72. Gattinoni, L.; Powell, D.J.; Rosenberg, S.A.; Restifo, N.P. Adoptive immunotherapy for cancer: Building on success. Nat. Rev. Immunol. 2006, 6, 383–393. [CrossRef] [PubMed]

73. Ruella, M.; Kalos, M. Adoptive immunotherapy for cancer. Immunol. Rev. 2014, 257, 14–38. [CrossRef] [PubMed]

74. Sharma, P.; Allison, J.P. The future of immune checkpoint therapy. Science 2015, 348, 56–61. [CrossRef] [PubMed]

75. Dudley, M.E.; Wunderlich, J.R.; Shelton, T.E.; Even, J.; Rosenberg, S.A. Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients. J. Immunother. 2003, 26, 332–342. [CrossRef] [PubMed]

76. Dudley, M.E.; Wunderlich, J.R.; Yang, J.C.; Sherry, R.M.; Topalian, S.L.; Restifo, N.P.; Royal, R.E.; Kammula, U.; White, D.E.; Mavroukakis, S.A.; et al. Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients with Refractory Metastatic Melanoma. J. Clin. Oncol. 2005, 23, 2346–2357. [CrossRef]

77. Rosenberg, S.A.; Packard, B.S.; Aebersold, P.M.; Solomon, D.; Topalian, S.L.; Toy, S.T.; Simon, P.; Lotze, M.T.; Yang, J.C.-H.; Seipp, C.A.; et al. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. N. Engl. J. Med. 1988, 319, 1676–1680. [CrossRef] [PubMed]

78. Itzhaki, O.; Hovav, E.; Ziporen, Y.; Levy, D.; Kubi, A.; Zikich, D.; Hershkovitz, L.; Treves, A.J.; Shalmon, B.; Zippel, D.; et al. Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy. J. Immunother. 2011, 34, 212–220. [CrossRef]
Cancers 2021, 13, 456

79. Radvanyi, L.; Bernatchez, C.; Zhang, M.; Fox, P.S.; Miller, P.; Chacon, J.; Wu, R.; Lizee, G.; Mahoney, S.; Alvarado, G.; et al. Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. *Clin. Cancer Res.* 2012, 18, 6758–6770. [CrossRef]

80. Andersen, R.; Donia, M.; Ellebaek, E.; Borch, T.H.; Kongsted, P.; Iversen, T.Z.; Hölmich, L.R.; Hendel, H.W.; Met, Ø.; Andersen, M.H.; et al. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. *Clin. Cancer Res.* 2016, 22, 3734–3745. [CrossRef]

81. Besser, M.J.; Shapira-Frommer, R.; Treves, A.J.; Zippel, D.; Itzhaki, O.; Hershkovitz, L.; Levy, D.; Kubi, A.; Ohayon, Y.; et al. Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. *Clin. Cancer Res.* 2013, 19, 4792–4800. [CrossRef] [PubMed]

82. Piön-Thomas, S.; Kuhn, L.; Ellwanger, S.; Janssen, W.; Royster, E.; Marzban, S.; Kudchadkar, R.; Zager, J.; Gibney, G.; Sondak, V.K.; et al. Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma. *J. Immunother.* 2012, 35, 615–620. [CrossRef] [PubMed]

83. Rosenberg, S.A.; Yang, J.C.; Sherry, R.M.; Kammula, U.S.; Hughes, M.S.; Phan, G.Q.; Citrin, D.E.; Restifo, N.P.; Robbins, P.F.; Wunderlich, J.R.; et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. *Clin. Cancer Res.* 2011, 17, 4550–4557. [CrossRef] [PubMed]

84. Freedman, R.S.; Tomasovic, B.; Templin, S.; Atkinson, E.N.; Kudelka, A.; Edwards, C.L.; Platsoucas, C.D. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. *J. Immunol. Methods* 1994, 167, 145–160. [CrossRef]

85. Ioanides, C.G.; Freedman, R.S.; Platsoucas, C.D.; Rashed, S.; Kim, Y.P. Cytoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. *J. Immunol.* 1991, 146, 1700–1707.

86. Fujita, K.; Ikarashi, H.; Takakuwa, K.; Kodama, S.; Tokunaga, A.; Takahashi, T.; Tanaka, K. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. *Clin. Cancer Res.* 1995, 1, 501–507.

87. Aoki, Y.; Takakuwa, K.; Kodama, S.; Tanaka, K.; Takahashi, M.; Tokunaga, A.; Takahashi, T. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. *Cancer Res.* 1991, 51, 1934–1939.

88. Freedman, R.S.; Platsoucas, C.D. Immunotherapy for peritoneal ovarian carcinoma metastasis using Ex Vivo expanded tumor infiltrating lymphocytes. *Cancer Treat. Res.* 1996, 82, 115–146. [CrossRef]

89. Webb, J.R.; Milne, K.; Watson, P.; DeLeeuw, R.J.; Nelson, B.H. Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer. *Clin. Cancer Res.* 2014, 20, 434–444. [CrossRef]

90. Hilders, C.G.J.M.; Ras, L.; Van Eendenburg, J.D.H.; Nooyen, Y.; Fleuren, G.J. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. *Int. J. Cancer* 1994, 57, 805–813. [CrossRef]

91. Yannelli, J.R.; Hyatt, C.; McConnell, S.; Hines, K.; Jacknin, L.; Parker, L.; Sanders, M.; Rosenberg, S.A. Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. *Int. J. Cancer* 1996, 65, 413–421. [CrossRef]

92. Turcotte, S.; Gros, A.; Hogan, K.; Tran, E.; Hinrichs, C.S.; Wunderlich, J.R.; Dudley, M.E.; Rosenberg, S.A. Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy. *J. Immunol.* 2013, 191, 2217–2225. [CrossRef]

93. Andersen, R.; Westergaard, M.C.W.; Kjeldsen, J.W.; Mueller, A.; Pedersen, N.W.; Hadrup, S.R.; Met, Ø.; Seliger, B.; Kromann-Andersen, B.; Hasselager, T.; et al. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy. *Cancer Immunol. Res.* 2018, 6, 222–235. [CrossRef]

94. Ho, W.Y.; Blattman, J.N.; Dosssett, M.L.; Yee, C.; Greenberg, P.D. Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction. *Cancer Cell* 2003, 3, 431–437. [CrossRef]

95. Zhu, Y.; Chen, L. CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert. *Clin. Cancer Res.* 2014, 20, 3–5. [CrossRef]

96. Shi, H.; Qi, X.; Ma, B.; Cao, Y.; Wang, L.; Sun, L.; Niu, H. The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies. *Chin. J. Cancer Res.* 2015, 27, 128–137.

97. Seliktar-Ofir, S.; Merhavi-Shoham, E.; Itzhaki, O.; Yunger, S.; Markel, G.; Schachter, J.; Besser, M.J. Selection of Shared and Neoantigen- Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation. *Front. Immunol.* 2017, 8, 1211. [CrossRef]

98. June, C.H.; O’Connor, R.S.; Kawalekar, O.U.; Ghassemi, S.; Milone, M.C. CAR T cell immunotherapy for human cancer. *Science* 2018, 359, 1361–1365. [CrossRef]

99. Zhao, Z.; Condomines, M.; Van Der Stegen, S.J.; Perna, F.; Kloss, C.C.; Gunset, G.; Plotkin, J.; Sadelain, M. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. *Cancer Cell* 2015, 28, 415–428. [CrossRef]
102. Kawalekar, O.U.; O’Connor, R.S.; Fraitetta, J.A.; Guo, L.; Megettigan, S.E.; Posey, A.D.; Patel, P.R.; Guedan, S.; Scholler, J.; Keith, B.; et al. Distinct Signaling of Co-receptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. *Immunity* 2016, 44, 380–390. [CrossRef]

103. Houot, R.; Goldstein, M.J.; Kohrt, H.E.; Myklebust, J.H.; Diehn, M.; Lin, J.T.; Irish, J.M.; Torchia, J.A.; Kolstad, A.; Chen, L.; et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. *Blood* 2009, 114, 3431–3438. [CrossRef]

104. Palazón, A.; Teijeira, A.; Martínez-Forero, I.; Hervas-Stubbs, S.; Roncal, C.; Peñuelas, I.; Dubrot, J.; Morales-Kastresana, A.; Pérez-Gracia, J.L.; Ochoa, M.C.; et al. Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes. *Cancer Res.* 2011, 71, 801–811. [CrossRef]

105. Morales-Kastresana, A.; Catalán, E.; Hervás-Stubbbs, S.; Palazón, A.; Azpilikueta, A.; Bolaños, E.; Anel, A.; Pardo, J.; Melero, I. Essential specificity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb. *J. Immunother. Cancer* 2013, 1. [CrossRef]

106. Shi, W.; Siemann, D.W. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. *Anti-cancer. Res.* 2006, 26, 3445–3453.

107. Chacon, J.A.; Wu, R.C.; Sukhumalchandra, P.; Molldrem, J.J.; Sarnaik, A.; Pilon-Thomas, S.; Weber, J.; Hwu, P.; Radvanyi, L. Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy. *PloS ONE* 2013, 8, e60031. [CrossRef]

108. Melero, I.; Hirschhorn-Cymerman, D.; Morales-Kastresana, A.; Sanmamed, M.F.; Wolchok, J.D. Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells. *Clin. Cancer Res.* 2013, 19, 1044–1053. [CrossRef]

109. Melero, I.; Grimaldi, A.M.; Perez-Gracia, J.L.; Ascierto, P.A. Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. *Clin. Cancer Res.* 2013, 19, 997–1008. [CrossRef]

110. Madireddi, S.; Eun, S.-Y.; Lee, S.-W.; Nemčovičová, I.; Mehta, A.K.; Zajonc, D.M.; Nishi, N.; Niki, T.; Hirashima, M.; Croft, M. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. *J. Exp. Med.* 2014, 211, 1433–1448. [CrossRef]

111. Chu, D.-T.; Nguyen, D.B.; Nguyen, K.H.; Van Thanh, V.; Nga, V.T.; Ngoc, V.T.N.; Dao, D.T.A.; Hoan, L.N.; Hung, N.P.; et al. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. *Int. J. Mol. Sci.* 2019, 20, 1822. [CrossRef]

112. Wei, H.; Zhao, L.; Li, W.; Fan, K.; Qian, W.; Hou, S.; Wang, H.; Dai, M.; Hellstrom, I.; Hellstrom, K.E.; et al. Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin. *PloS ONE* 2013, 8, e84927. [CrossRef] [PubMed]

113. Kim, Y.H.; Choi, B.K.; Oh, H.S.; Kang, W.J.; Mittler, R.S.; Kwon, B.S. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. *Mol. Cancer Ther.* 2009, 8, 469–478. [CrossRef] [PubMed]

114. Westwood, J.A.; Matthews, G.M.; Shortt, J.; Faulkner, D.; Pegrann, H.J.; Duong, C.P.; Chesi, M.; Bergsagel, P.L.; Sharp, L.L.; Huh, R.D.; et al. Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. *Leuk. Res.* 2014, 38, 948–954. [CrossRef] [PubMed]

115. Kocak, E.; Lute, K.; Chang, X.; May, K.F.; Exten, K.R.; Zhang, H.; Abdessalam, S.F.; Lehman, A.M.; Jarjoura, D.; Zheng, P.; et al. Combination Therapy with Anti–CTLA-4, Anti-CD137, and Anti-PD1. *Cancer Res.* 2013, 73, 7276–7284. [CrossRef] [PubMed]

116. Simeone, E.; Ascierto, P.A. Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1. *J. Immunotoxicol.* 2012, 9, 241–247. [CrossRef]

117. Dai, M.; Wei, H.; Yip, Y.Y.; Feng, Q.; He, K.; Popov, V.; Hellstrom, I.; Hellstrom, K.E. Long-lasting Complete Regression of Hepatocellular Carcinoma Mouse Model. *Ochoa, C.; Rouzaut, A.; et al. Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model. *Clin. Cancer Res.* 2013, 19, 6151–6162. [CrossRef]

118. Ascierto, P.A.; Kalos, M.; Scher, D.A.; Callahan, M.K.; Wolchok, J.D. Biomarkers for Immunostimulatory Monoclonal Antibodies. *Clin. Cancer Res.* 2013, 19, 1009–1020. [CrossRef]

119. Ascierto, P.A.; Capone, M.; Urba, W.J.; Bifulco, C.; Botti, G.; Lugli, A.; Marincola, F.M.; Ciliberto, G.; Galon, J.; Fox, B.A. The additional facet of immunoscore: Immunoprofiling as a possible predictive tool for cancer treatment. *J. Transl. Med.* 2013, 11, 54. [CrossRef]

120. Morales-Kastresana, A.; Sanmamed, M.F.; Rodriguez, I.; Palazón, A.; Martinez-Forero, I.; Labiano, S.; Hervás-Stubbbs, S.; Sangro, B.; Ochoa, C.; Rouzaut, A.; et al. Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model. *Clin. Cancer Res.* 2013, 19, 6151–6162. [CrossRef]

121. Xu, D.; Gu, P.; Pan, P.-Y.; Li, Q.; Sato, A.I.; Chen, S.-H. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. *Int. J. Cancer* 2004, 109, 499–506. [CrossRef]

122. Quetglas, J.I.; Dubrot, J.; Bezuartea, J.; Sanmamed, M.F.; Hervás-Stubbbs, S. Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12. *Mol. Ther.* 2012, 20, 1664–1675. [CrossRef] [PubMed]

123. Tirapu, I.; Arina, A.; Mazzolini, G.; Duarte, M.; Alfaro, C.; Feijoo, E.; Qian, C.; Chen, L.; Prieto, J.; Melero, I. Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. *Int. J. Cancer* 2004, 110, 51–60. [CrossRef] [PubMed]

124. Hidehito, S.; Li, Q.; Shreiner, A.B.; Okuyama, R.; Jure-Kunkel, M.N.; Teitz-Tennenbaum, S.; Chang, A.E. Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines. *Cancer Res.* 2004, 64, 8411–8419. [CrossRef]
125. Westwood, J.A.; Hunnam, T.C.U.P.; Pegram, H.J.; Hicks, R.J.; Darcy, P.K.; Kershaw, M.H. Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice. *PloS ONE* 2014, 9, e95847. [CrossRef]

126. Ko, E.; Luo, W.; Peng, L.; Wang, X.; Ferrone, S. Mouse Dendritic-Endothelial Cell Hybrids and 4-1BB Costimulation Elicit Antitumor Effects Mediated by Broad Antiangiogenic Immunity. *Cancer Res.* 2007, 67, 7875–7884. [CrossRef] [PubMed]

127. Chen, S.-H.; Pharm-Nguyen, K.B.; Martinet, O.; Huang, Y.; Yang, W.; Thung, S.N.; Chen, L.; Mittler, R.; Woo, S.L. Rejection of Disseminated Metastases of Colon Carcinoma by Synergism of IL-12 Gene Therapy and 4-1BB Costimulation. *Mol. Ther.* 2000, 2, 39–46. [CrossRef]

128. Li, B.; Lin, J.; VanRoey, M.; Jure-Kunkel, M.; Jooss, K. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. *Clin. Immunol.* 2007, 125, 76–87. [CrossRef]

129. Ju, S.-A.; Cheon, S.-H.; Park, S.-M.; Tam, N.Q.; Kim, Y.M.; An, W.G.; Kim, B.-S. Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. *Int. J. Cancer* 2008, 122, 2784–2790. [CrossRef]

130. John, L.B.; Howland, L.J.; Flynn, J.K.; West, A.C.; Devaud, C.; Duong, C.P.; Stewart, T.J.; Westwood, J.A.; Guo, Z.S.; Bartlett, D.L.; et al. Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer. *Cancer Res.* 2012, 72, 1651–1660. [CrossRef]

131. Kobayashi, T.; Doff, B.L.; Rearden, R.C.; Leggatt, G.R.; Matteisolo, S.R. NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. *OncoImmunology* 2015, 4, e990793. [CrossRef]

132. Kwong, B.; Gai, S.A.; Elkhader, J.; Wittrup, K.D.; Irvine, D.J. Localized Immunotherapy via Liposome-anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity. *Cancer Res.* 2013, 73, 1547–1558. [CrossRef]

133. Curran, M.A.; Kim, M.; Montalvo, W.; Al-Shamkhani, A.; Allison, J.P. Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production. *PloS ONE* 2011, 6, e19499. [CrossRef] [PubMed]

134. Smith, S.E.; Hoelzinger, D.B.; Dominguez, A.L.; Van Snick, J.; Lustgarten, J. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing anti-tumor responses. *Cancer Immunol. Immunother.* 2011, 60, 1777–1787. [CrossRef] [PubMed]

135. Ugolini, A.; Tyurin, V.A.; Tyurina, Y.Y.; Tcyganov, E.N.; Donthireddy, L.; Kagan, V.E.; Gabrilovich, D.; Veglia, F. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. *JCI Insight* 2020, 5, 138581. [CrossRef] [PubMed]

136. Guo, Z.; Cheng, D.; Xia, Z.; Luan, M.; Wu, L.; Wang, G.; Zhang, S. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. *J. Transl. Med.* 2013, 11, 215. [CrossRef] [PubMed]

137. Chester, C.; Sammamed, M.E.; Wang, J.; Melero, I. Immunotherapy targeting 4-1BB: Mechanistic rationale, clinical results, and future strategies. *Blood* 2018, 131, 49–57. [CrossRef]

138. Segal, N.H.; Logan, T.F.; Hodi, F.S.; McDermott, D.; Melero, I.; Hamid, O.; Schmidt, H.; Robert, C.; Chiarion-Sileni, V.; Ascierto, P.A.; et al. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. *Clin. Cancer Res.* 2017, 23, 1929–1936. [CrossRef]

139. Segal, N.H.; Gopal, A.K.; Bhata, S.; Kohrt, H.E.; Levy, R.; Pishvaian, M.J.; Houot, R.; Bartlett, N.; Nghiem, P.; Kronenberg, S.A.; et al. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. *J. Clin. Oncol.* 2014, 32, 3007. [CrossRef]

140. Segal, N.H.; He, A.R.; Doi, T.; Levy, R.; Bhata, S.; Pishvaian, M.J.; Cesari, R.; Chen, Y.; Davis, C.B.; Huang, B.; et al. Phase I Study of Single-Agent Utomilumab (PF-05082567), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. *Clin. Cancer Res.* 2018, 24, 1816–1823. [CrossRef]

141. Tolcher, A.W.; Szoln, M.; Hu-Lieskov, S.; Papadopoulos, K.P.; Patnaik, A.; Rasco, D.W.; Di Gravio, D.; Huang, B.; Gambhire, D.; Chen, Y.; et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrozumab (MK-3475) in Patients with Advanced Solid Tumors. *Clin. Cancer Res.* 2016, 22, 5349–5357. [CrossRef]

142. Tolcher, A.W.; Szoln, M.; Hu-Lieskov, S.; Papadopoulos, K.P.; Patnaik, A.; Rasco, D.W.; Di Gravio, D.; Huang, B.; Gambhire, D.; Chen, Y.; et al. Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors. *J. Clin. Oncol.* 2016, 23, 5349–5357. [CrossRef]

143. Cohen, E.E.W.; Pishvaian, M.J.; Shepard, D.R.; Wang, D.; Weiss, J.; Johnson, M.L.; Chung, C.H.; Chen, Y.; Huang, B.; Davis, C.B.; et al. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. *J. Immunother. Cancer* 2019, 7, 342. [CrossRef] [PubMed]

144. Gopal, A.K.; Bartlett, N.L.; Levy, R.; Houot, R.; Smith, S.D.; Segal, N.H.; Thall, A.D.; Mugundu, G.; Huang, B.; Davis, C.; et al. A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL. *J. Clin. Oncol.* 2015, 33, 3004. [CrossRef]

145. Hinne, M.J.; Aiba, R.S.B.; Jaquin, T.J.; Berger, S.; Dür, M.C.; Schlosser, C.; Allersdorfer, A.; Wiedenmann, A.; Matschner, G.; Schüler, J.; et al. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-AntiCinax Fusion PRS-343. *Clin. Cancer Res.* 2019, 25, 5878–5889. [CrossRef] [PubMed]

146. Pila-Paul, S.; Bendell, J.; Tolcher, A.; Hurvitz, S.; Patnaik, A.; Shroff, R.; Pohlmann, P.; Zettl, M.; Hahn, N.; Krishnamurthy, A.; et al. O82 A phase 1 dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies. *J. Immunother. Cancer* 2020. [CrossRef]

147. Nelson, M.; Miller, R.; Nilsson, A.; Ljung, L.; Chuny, A.; Mcmahan, C.; Bienvenue, D.; Askmyr, M.; Hernandez-Hoyos, G.; Fritzell, S. 851 Potent tumor-directed T cell activation and In Vivo tumor inhibition induced by a 4-1BB x ST4 ADAPTIR™ bispecific antibody. *J. Immunother. Cancer* 2020. [CrossRef]
148. Claus, C.; Ferrara, C.; Xu, W.; Sam, J.; Lang, S.; Uhlenbrock, F.; Albrecht, R.; Herter, S.; Schlenker, R.; Hüsper, T.; et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci. Transl. Med. 2019, 11, eaav5989. [CrossRef]

149. Compte, M.; Harwood, S.L.; Muñoz, I.G.; Navarro, R.; Zonca, M.; Perez-Chacon, G.; Erce-Llamazares, A.; Merino, N.; Tapia-Galisteo, A.; Cuesta, A.M.; et al. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. Nat. Commun. 2018, 9, 4809. [CrossRef]

150. Nuti, M.; Zizzari, I.; Botticelli, A.; Rughetti, A.; Marchetti, P. The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one. Cancer Treat. Rev. 2018, 70, 41–46. [CrossRef]

151. Bonaventura, P.; Shekarian, T.; Alcazer, V.; Valladeau-Guilemond, J.; Valsesia-Wittmann, S.; Amigorena, S.; Caux, C.; Depil, S. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front. Immunol. 2019, 10, 168. [CrossRef]

152. Tormoen, G.; Crittenden, M.R.; Gough, M.J. Role of the immunosuppressive microenvironment in immunotherapy. Adv. Radiat. Oncol. 2018, 3, 520–526. [CrossRef] [PubMed]

153. Labani-Motlagh, A.; Ashja-Mahdavi, M.; Loskog, A. The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Front. Immunol. 2020, 11, 940. [CrossRef] [PubMed]

154. Veglia, F.; Perego, M.; Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 2018, 19, 108–119. [CrossRef] [PubMed]

155. Jensen, S.M.; Maston, L.D.; Gough, M.J.; Ruby, C.E.; Redmond, W.L.; Crittenden, M.; Li, Y.; Puri, S.; Poehlein, C.H.; Morris, N.; et al. Signaling Through OX40 Enhances Antitumor Immunity. Semin. Oncol. 2010, 37, 524–532. [CrossRef] [PubMed]

156. Croft, M.; So, T.; Duan, W.; Soroosh, P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol. Rev. 2009, 229, 173–191. [CrossRef] [PubMed]

157. Linch, S.N.; McNamara, M.J.; Redmond, W.L. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front. Oncol. 2015, 5, 34. [CrossRef]

158. Fu, Y.; Lin, Q.; Zhang, Z.; Zhang, L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm. Sin. B 2020, 10, 414–433. [CrossRef]